DEPARTMENT OF RHEUMATOLOGY
|
|
|
- Jonas Griffin
- 5 years ago
- Views:
Transcription
1 DEPARTMENT OF RHEUMATOLOGY PG Teaching Schedule Theory (8 30 am to 9am) DATE TOPIC PRESENTER FACULTY 01/10/16 Approach to Arthritis Dr. Sandeep Dr. Suma Balan 03/10/16 Cardiovascular risk in Rheumatic Disease Dr. Sandeep Dr. Suma Balan 04/10/16 Diagnostic tests and procedures in Rheumatic Disease Dr. Sandeep Dr. Suma Balan 05/10/16 Imaging Modalities in Rheumatic Disease Dr. Sandeep Dr. Suma Balan 01/11/16 Early Arthritis Dr. Vishnu Dr.Mithun C B 02/11/16 Etiology and Pathognesis Dr. Vishnu Dr.Mithun C B 03/11/16 Undifferentiated Arthritis Dr. Vishnu Dr.Mithun C B 04/11/16 Reactive Arthritis Dr. Vishnu Dr.Mithun C B 01/12/16 Early Rheumatoid Arthritis Dr. Sandeep Dr.Mithun C B 02/12/16 Clinical Features Dr. Sandeep Dr.Mithun C B 03/12/16 Treatment of Rheumatoid Arthritis Dr. Sandeep Dr.Mithun C B 02/01/17 Late Rheumatoid Arthritis Dr.Vishnu Dr. Jyothi Srikanth 03/01/17 Overlap Syndrome Dr.Vishnu Dr. Jyothi Srikanth 04/01/17 Sjogrn Syndrome Dr.Vishnu Dr. Jyothi Srikanth
2 SEMINARS (3pm to 4pm) DATE TOPIC PRESENTER FACULTY 03/10/16 Nail Fold Cappilaroscopy Dr. Sarah Dr. Suma Balan 10/10/16 Dermatomyositis Dr. Veena Dr.Mithun C B 17/10/16 Behcet s Disease Dr. Sandeep Dr. Suma Balan 24/10/16 Sarcoidosis Dr.Vishnu Dr. Jyothi Srikanth 31/10/16 Juvenile Idiopathic Arthritis Dr. Sandeep Dr. Vishal Marwaha 07/11/16 Approach to Gangrene Dr. Vishnu Dr. Suma Balan 14/11/16 Interpretation of lab investigations in Dr.Sandeep Dr. Mithun C B autoimmune disease 21/11/16 Methotrexate Mechanism of Action Dr. Vishnu Dr. Vishal Marwaha 28/11/16 Interpretation of labs Dr. Sandeep Dr. Suma Balan 05/12/16 Methotrexate in Pregnancy Dr. Vishnu Dr. Jyothi Srikanth 12/12/16 ANA Part one Dr. Sandeep 19/12/16 ANA Part two Dr. Vishnu 26/12/16 ANA Part three Dr. Sandeep 02/0116 Methotrexate Dosing,Oral vs Sub cutaneous route, Perioperative adjustments. 09/01/17 Joint examination and Intra articular injection Shoulder joint. 16/01/17 Joint examination and Intra articular injection elbow joint. 23/01/17 Joint examination and Intra articular injection wrist joint Dr. Vishnu Dr. Sandeep Dr. Vishnu Dr. Sandeep Dr. Suma Balan Dr. Jyothi Srikanth Dr. Vishal Marwaha Dr. Suma Balan
3 30/01/17 Joint examination and Intra articular injection- metacarpsl joint Dr. Vishnu CASE PRESENTATIONS (8:30 am to 9:30am) DATE DIAGNOSIS PRESENTER FACULTY 05/10/16 Axial SPA Dr. Vishnu Dr. Suma Balan 12/10/16 Behcet s disease Dr. Sandeep Dr. MIthun C B 19/10/16 Refractory RA Dr. Vishnu Dr. Suma Balan 26/10/16 Sarcoidosis Dr. Sandeep Dr. Jyothi Srikanth 02/11/16 Sarcoidosis Dr. Vishnu Dr. Vishal Marwaha 09/11/16 Wegner s Granulomatosis relapse Dr. Sandeep Dr. Mithun C B 16/11/16 Hypercalcemia with Purpura Dr.Vishnu Dr. Mithun C B 23/11/16 Churg Strauss syndrome Dr. Sandeep Dr. Suma Balan 30/11/16 Undifferentiated Connective Tissue Disease Dr.Vishnu Dr. Jyothi Srikanth 07/12/16 Lupus Nephritis Dr. Sandeep Dr. Vishal Marwaha 14/12/16 Chronic Sarcoidosis Dr.Vishnu Dr. Jyothi Srikanth 21/12/16 Behcets syndrome Dr. Sandeep Dr. Vishal Marwaha 28/12/16 Juvenile Idiopathic Arthritis Dr.Vishnu Dr. Mithun C B 04/01/17 Sine Scleroderma Dr. Sandeep Dr. Suma Balan 11/01/17 Rheumatoid Arthritis Dr.Vishnu Dr. Jyothi Srikanth 18/01/17 Henoch Schonlein purpura Dr. Sandeep Dr. Vishal Marwaha 25/01/17 Sarcoidosis with ocular and lung involvement Dr.Vishnu Dr. Mithun C B
4 BEDSIDE TEACHING (4pm to 5pm) DATE TOPIC FACULTY 06/10/16 Behcet s Disease Dr Vishal Marwaha 13/10/16 Henoch Schonlein purpura Dr. Mithun CB 20/10/16 Oligo-Articular JIA Dr. Suma Balan 27/10/16 Peripheral Spondyloarthopathy Dr. Jyothi S. 03/11/16 Polyarticular JIA Dr. Suma Balan 10/11/16 Axial Spondyloarthritis - Refractory disease Dr. Mithun CB 17/11/16 Sine Scleroderma with Severe PAH -RV dysfunction Dr Vishal Marwaha 01/12/16 Idiopathic Sceleritis Dr. Mithun CB 08/12/16 Systemic Onset JIA Dr. Suma 15/12/16 Dermatomyositis Dr. Jyothi S. 22/12/16 Kawasaki s Disaease Dr. Suma 29/12/16 Refractory Polymyositis Dr. Mithun CB 05/01/17 Limited systemic sclerosis with severe Raynaud's Dr Vishal Marwaha phenomenon 12/01/17 RA with Vascultis 19/01/17 PUO with Polyarthritis under evaluation Dr Vishal Marwaha
5 JOURNAL CLUBS (4pm to 5pm) DATE TOPIC FACULTY 04/10/16 Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related ILD (SLS II): a RCT parallel group trial 11/10/16 BSR and BHPR guidelines for the treatment of systemic sclerosis. 25/10/16 Adalimumab in Patients with Active Noninfectious Uveitis. N Engl J Med Dr Suma Balam Dr Jyothi Srikanth 01/11/16 Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A RCT; JAMA Aug Dr Vishal Marwaha 15/11/16 Effect of Tabalumab in patients with RA who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, doubleblind study - Ann Rheum Dis /11/16 Arthritis & Rheumatology article: Lesinurad Combined With Allopurinol: A Randomized, Double- Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol Dr Suma Balam 06/12/16 Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis - PRECISION Trial 13/12/16 Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double- Dr Jyothi Srikanth Dr Vishal Marwaha
6 Blind, Placebo-Controlled Trial 27/12/16 Rituximab Versus Azathioprine to Maintain Remission of ANCA-Associated Vasculitides (MAINRITSAN): Follow-up at 60 Months 03/01/17 Combination Therapy of Apremilast and Biologic Agent As a Safe Option of Psoriatic Arthritis and Psoriasis 10/01/17 Non TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial 31/01/17 Coronary Artery Complication in Kawasaki Disease and the Importance of Early Intervention: A Systematic Review and Meta-analysis. Dr Suma Balam Dr Jyothi Srikanth PROCEDURES MONTH PROCEDURES Oct Nov Dec Jan Vishal Marwaha, HOD Department Of Rheumatology AIMS Kochi
RHEUMATOLOGY OVERVIEW. Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center
RHEUMATOLOGY OVERVIEW Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center What is Rheumatology? Medical science devoted to the rheumatic diseases
Overview of Paediatric Investigation Plan (PIP) in Paediatric Rheumatology
Overview of Paediatric Investigation Plan (PIP) in Paediatric Rheumatology Paediatric Rheumatology Expert Meeting, London 4 th December 29 Dr. Richard Veselý, Dr. Emma Sala Soriano Paediatric Investigation
ArLAR 2018, the Pan Arab Rheumatology Conference in conjunction with the 1st OSR meeting 23 to 25 February 2018, Muscat, Oman.
ArLAR 2018, the Pan Arab Rheumatology Conference in conjunction with the 1st OSR meeting 23 to 25 February 2018, Muscat, Oman. to change at any time www.arlar.org info@arlar.org #ArLAR2018 Thursday, 22
Financial Report. Moving Together
Financial Report 2013 Moving Together Our Purpose To improve the quality of life of people who have, or are at risk of developing musculoskeletal conditions. Our Values Respect and integrity Service and
Rheumatology Suggested Reading List. Compiled by Rebecca Sharim MD. Updated: 4/6/17
Rheumatology Suggested Reading List Compiled by Rebecca Sharim MD Updated: 4/6/17 Rheumatoid Arthritis: 1994: Elliott, Michael J., et al. "Randomised double-blind comparison of chimeric monoclonal antibody
INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximab-abda)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Remicade, Renflexis and Inflectra are tumor necrosis factor (TNFα) blockers. Tumor necrosis factor is an endogenous protein that regulates a number of physiologic
Kelley's Textbook of Rheumatology. 2 Volume Set. Text with Internet Access Code for Premium Consult Edition
Kelley's Textbook of Rheumatology. 2 Volume Set. Text with Internet Access Code for Premium Consult Edition Firestein, G ISBN-13: 9781437717389 Table of Contents VOLUME I STRUCTURE AND FUNCTION OF BONE,
Essential Rheumatology. Dr Ellen Bruce Consultant Rheumatologist CMFT
Essential Rheumatology Dr Ellen Bruce Consultant Rheumatologist CMFT Saving the best for last! Apparently people recall best the first and last thing they re told. Far too difficult to include everything.
JuvenileIdiopathicArthritis. Dr Johan Siebert
JuvenileIdiopathicArthritis Dr Johan Siebert 1 NORMAL DIARTHRODIAL JOINT Synovial is a thin membrane enclosing the joint space The joint space contains fluid that bathes the joint and reduces friction
2/23/18. Disclosures. Rheumatic Diseases of Childhood. Making Room for Rheumatology. I have nothing to disclose. James J.
Making Room for Rheumatology James J. Nocton, MD Disclosures I have nothing to disclose Rheumatic Diseases of Childhood Juvenile Idiopathic Arthritis (JIA) Systemic Lupus Erythematosus (SLE) Juvenile Dermatomyositis
Effective Health Care Program
Comparative Effectiveness Review Number 28 Effective Health Care Program Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA) Executive Summary Background
Coverage Criteria: Express Scripts, Inc. monograph dated 12/15/ months or as otherwise noted by indication
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Kineret (anakinra subcutaneous injection) Commercial HMO/PPO/CDHP
A CRP B FBC C LFT D blood culture E uric acid
1 A 39 year old lady with rheumatoid arthritis is admitted to hospital with a hot, swollen and painful right knee. Which is the most important blood test? A CRP B FBC C LFT D blood culture E uric acid
INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 6 years of age or older 1. Moderate to severe Crohn s disease (CD) a. Patient has fistulizing disease
Rheumatologic Laboratory Testing and Common Hematological Drugs. September 10, 2013 Dr. Jeffrey C. Hoschek, MD, FAAP
Rheumatologic Laboratory Testing and Common Hematological Drugs September 10, 2013 Dr. Jeffrey C. Hoschek, MD, FAAP THERE ARE MULTIPLE TESTS USED TO BOTH SCREEN FOR AND MAKE THE DIAGNOSIS OF MANY RHEUMATOLOGICAL
CONTENT OUTLINE. Pediatric Rheumatology
THE AMERICAN BOARD OF PEDIATRICS CONTENT OUTLINE Pediatric Rheumatology Subspecialty In-Training, Certification, and Maintenance of Certification (MOC) Examinations INTRODUCTION This document was prepared
A. Smržová. III. Interní klinika FN Olomouc nefrologická, revmatologická a endokrinologická
A. Smržová III. Interní klinika FN Olomouc nefrologická, revmatologická a endokrinologická Systemic vasculitis destructive inflamatory of the walls of blood vessels. Pathologist Inflammatory destruction
Abatacept (Orencia) for active rheumatoid arthritis. August 2009
Abatacept (Orencia) for active rheumatoid arthritis August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
Rheumatology and Internal Diseases Clinic of the Central Clinical Hospital in Warsaw 137 Woloska St. WARSAW POLAND prof. Małgorzata Wisłowska
Rheumatology and Internal Diseases Clinic of the Central Clinical Hospital in Warsaw 137 Woloska St. WARSAW 02-507 POLAND prof. Małgorzata Wisłowska MD, PhD 1 Klinika Chorób Wewnętrznych i Reumatologii
Jeopardy. What s the rash? $100 $100 $100 $100 $100 $200 $200 $200 $200 $200 $300 $300 $300 $300 $300 $400 $400 $400 $400 $400
Jeopardy Antibodies & more antibodies Aching joints What s the rash? Potpourri Image Challenge $100 $100 $100 $100 $100 $200 $200 $200 $200 $200 $300 $300 $300 $300 $300 $400 $400 $400 $400 $400 $500 $500
Biologics in rheumatic diseases
Biologics in rheumatic diseases Dimitrios A. Vassilopoulos, MD Joint Rheumatology Program Clinical Immunology-Rheumatology Unit 2 nd Department of Medicine and Laboratory National and Kapodistrian University
The Hospital for Sick Children Technology Assessment at SickKids (TASK)
The Hospital for Sick Children Technology Assessment at SickKids (TASK) THE USE OF BIOLOGIC RESPONSE MODIFIERS IN POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS Report No. 2010-01 Date: January 11,
APPLICATION FOR SPECIAL AUTHORITY. Subsidy for Tocilizumab
APPLICATION FOR SPECIAL AUTHORITY Fm SA1781 Subsidy f Tocilizumab Application Categy Page Cytokine release syndrome - Initial application... 2 Previous use - Initial application... 2 Rheumatoid Arthritis
Competency Based Curriculum
Competency Based Curriculum Internal Medicine Residency Program The George Washington University Curriculum last updated on: 04/29/2009 Rotation: Division: Site: Director: Rheumatology Division of Rheumatology
Year In Review: VasculitisPers. Disclosures. Learning Objectives. none 4/16/2018. Describe new medications for the treatment of vasculitis
Year In Review: VasculitisPers Cailin Sibley, M.D., M.H.S. Director, Vasculitis Clinic April 27 th, 2018 NTEREST DISCLOSURE Disclosures none Learning Objectives Describe new medications for the treatment
Corporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: infliximab_remicade 5/2002 2/2017 2/2018 2/2017 Description of Procedure or Service Infliximab (REMICADE
Juvenile Idiopathic Arthritis (JIA)
Juvenile Idiopathic Arthritis (JIA) Kaveh Ardalan, MD, MS Division of Rheumatology Ann & Robert H. Lurie Children s Hospital of Chicago Assistant Professor, Pediatrics and Medical Social Sciences Northwestern
REFERRAL GUIDELINES: RHEUMATOLOGY
Outpatient Page 1 1 REFERRAL GUIDELINES: RHEUMATOLOGY Date of birth Demographic Contact details (including mobile phone) Clinical Reason for referral Duration of symptoms Essential Referral Content Referring
ORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION
UnitedHealthcare Community Plan Medical Benefit Drug Policy ORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION Policy Number: CS2018D0039J Effective Date: March 1, 2018 Table of Contents Page INSTRUCTIONS
Corporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: abatacept_orencia 4/2008 2/2018 2/2019 2/2018 Description of Procedure or Service Abatacept (Orencia ), a
Prior Authorization Policy
Prior Authorization Policy http://www.paramounthealthcare.com/providers Enbrel (etanercept) Pharmacy Benefit Commercial HMO/PPO/CDHP Setting Self-administered subcutaneous injection Medical Benefit N/A
BIOLOGIC THERAPY : A NEW OPTION FOR TREATMENT JUVENILE IDIOPATHIC ARTHRITIS DR TON THAT HOANG
BIOLOGIC THERAPY : A NEW OPTION FOR TREATMENT JUVENILE IDIOPATHIC ARTHRITIS DR TON THAT HOANG INTRODUCTION JIA is the most common chronic rheumatic inflammatory disease of childhood. If not successfully
Where has SARA gone? Prof. David Kane Consultant Rheumatologist Beacon & Tallaght Hospitals. Clinical Professor in Rheumatology Trinity College Dublin
Where has SARA gone? Prof. David Kane Consultant Rheumatologist Beacon & Tallaght Hospitals Clinical Professor in Rheumatology Trinity College Dublin 1 Reactive Arthritis Seronegative Asymmetrical Arthritis
Rheumatoid Arthritis
Rheumatoid Arthritis What is rheumatoid arthritis? Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the joints. Rheumatoid arthritis can also cause inflammation of
Corporate Medical Policy
Corporate Medical Policy Infliximab, Infliximab-dyyb, Infliximab-abda File Name: Origination: Last CAP Review: Next CAP Review: Last Review: infliximab 5/2002 2/2018 2/2019 7/2018 Description of Procedure
Center for Evidence-based Policy
P&T Committee Brief Targeted Immune Modulators: Comparative Drug Class Review Alison Little, MD Center for Evidence-based Policy Oregon Health & Science University 3455 SW US Veterans Hospital Road, SN-4N
4/16/2018. Demystifying weakness: how to approach refractory myositis. Objectives. Disclosures. Off-label uses for medications will be discussed
Demystifying weakness: how to approach refractory myositis Jemima Albayda, MD Assistant Professor Johns Hopkins Myositis center Disclosures Off-label uses for medications will be discussed Objectives To
MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 08/19/14 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:
RITUXAN (rituximab) Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline
Ad-Hoc Rheumatology Subcommittee of PTAC meeting held 8 March. (minutes for web publishing)
Ad-Hoc Rheumatology Subcommittee of PTAC meeting held 8 March 2011 (minutes for web publishing) Ad-Hoc Rheumatology Subcommittee minutes are published in accordance with the Terms of Reference for the
Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximababda)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.02 Subject: Infliximab Page: 1 of 13 Last Review Date: December 8, 2017 Infliximab Description Remicade
DRAFT FOR POC BOARD Clinical Commissioning Policy Proposition: Rituximab in Connective Tissue Disease associated Interstitial Lung Disease (adults)
Clinical Commissioning Policy Proposition: Rituximab in Connective Tissue Disease associated Interstitial Lung Disease (adults) Reference: NHS England A/14/X01 CHECK Information Reader Box (IRB) to be
Horizon Scanning Technology Summary. Adalimumab (Humira) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Adalimumab (Humira) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
Remicade (infliximab) Inflectra (infliximab-dyyb) Renflexis (infliximab-abda)
DRUG POLICY BENEFIT APPLICATION Remicade (infliximab) Inflectra (infliximab-dyyb) Renflexis (infliximab-abda) Benefit determinations are based on the applicable contract language in effect at the time
ORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION
ORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2018D0039J Effective Date: March 1, 2018 Table of Contents Page INSTRUCTIONS
Medical Coverage Guidelines are subject to change as new information becomes available.
ENBREL (etanercept) Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline
Diagnostic Tests in Rheumatic Disease: What s Old, What s New & What s Useful? COPYRIGHT
Diagnostic Tests in Rheumatic Disease: What s Old, What s New & What s Useful? Robert H. Shmerling, M.D. Beth Israel Deaconess Medical Center Boston, MA Diagnostic Tests in Rheumatic Disease: What's Old,
Skin cancers in patients treated with immunomodulating drugs. Manuelle Viguier, MD, PhD Dermatology department Saint-Louis Hospital Paris, France
Skin cancers in patients treated with immunomodulating drugs Manuelle Viguier, MD, PhD Dermatology department Saint-Louis Hospital Paris, France Immunomodulating drugs used in Methotrexate Mycophenolate
Small Vessel Vasculitis
Banff- Rocky Mountain Barry Kassen, MD, FRCPC,FACP Head, Division of Internal Medicine UBC/VGH/SPH Acting Head, Division of Community Internal Medicine November, 2009 Objectives 1. To understand small
UNFOLDING NATURE S ORIGAMI: MEDICAL TREATMENT OF TAKAYASU ARTERITIS AND GIANT CELL ARTERITIS
UNFOLDING NATURE S ORIGAMI: MEDICAL TREATMENT OF TAKAYASU ARTERITIS AND GIANT CELL ARTERITIS CanVasc meeting Montreal Nov 22 2012 Patrick Liang Service de rhumatologie Centre Hospitalier Universitaire
University of Bristol - Explore Bristol Research. Peer reviewed version. Link to published version (if available): / X.
Sen, E. S., & Ramanan, A. V. (2016). Biologic drugs in pediatric rheumatology. International Journal of Rheumatic Diseases, 19(6), 533-535. https://doi.org/10.1111/1756-185x.12924 Peer reviewed version
Staging of Type 1 Diabetes: Clinical Implications. April Deborah Hefty, MN, RN, CDE.
Staging of Type 1 Diabetes: TT Clinical Implications April 2016 Deborah Hefty, MN, RN, CDE dhefty@benaroyaresearch.org BRI s major contributions to type 1 diabetes research Identified type 1 diabetes susceptibility
SMALL TO MEDIUM VASCULITIS: RENAL ASPECT RATANA CHAWANASUNTORAPOJ UPDATE IN INTERNAL MEDICINE 2018
SMALL TO MEDIUM VASCULITIS: RENAL ASPECT RATANA CHAWANASUNTORAPOJ UPDATE IN INTERNAL MEDICINE 2018 OUTLINE Renal involvement in vasculitis Curr Rheumatol Rep 2013 Renal involvement in ANCA vasculitis GN***:
ACTEMRA (tocilizumab)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 1. Active Polyarticular Juvenile Idiopathic Arthritis (PJIA) b. Patient has an intolerance or has experienced
Orencia (abatacept) for Rheumatoid Arthritis. Media backgrounder
Orencia (abatacept) for Rheumatoid Arthritis Media backgrounder What is Orencia (abatacept)? Orencia (abatacept) is the first biologic agent to be available in both an intravenous (IV) and a self-injectable,
Medication Policy Manual. Topic: Otezla, apremilast Date of Origin: May 9, 2014
Medication Policy Manual Policy No: dru342 Topic: Otezla, apremilast Date of Origin: May 9, 2014 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1, 2015 IMPORTANT
RITUXAN (rituximab), NONONCOLOGIC USES
RITUXAN (rituximab), NONONCOLOGIC USES Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical
Horizon Scanning Technology Summary. Abatacept (Orencia) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Abatacept (Orencia) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
Index. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abatacept, for rheumatoid arthritis, 789 Acetaminophen, for low back pain, 735 Acupuncture for fibromyalgia, 753 for low back pain, 738
Rheumatology 101 A Pediatrician s Guide
Rheumatology 101 A Pediatrician s Guide Pediatric Staff and Alumni Day 2016 Dawn M. Wahezi, Yonit Sterba, Tamar Rubinstein Disclosures None Pick a Group Group 1 A child with a limp Group 2 ANA To test
Remicade (infliximab) DRUG.00002
Applicability/Effective Date *- Florida Healthy Kids Remicade (infliximab) DRUG.00002 Override(s) Prior Authorization Step Therapy Medications Remicade (infliximab) Approval Duration 1 year Comment Intravenous
Learning Objectives and Assessment Methodologies Combined Medicine-Pediatrics Rheumatology Elective
Learning Objectives and Assessment Methodologies Combined Medicine-Pediatrics Rheumatology Elective Overview: Med-Peds PGY2 s, PGY3 s and PGY4 s can elect to spend one four-week rotation with the adult
CENTRAL NERVOUS SYSTEM VASCULITIS
What is central nervous system (CNS) vasculitis? Central nervous system (CNS) vasculitis is among a family of rare disorders characterized by inflammation of the blood vessels, which restricts blood flow
PHARMACY POLICY STATEMENT Ohio Medicaid
DRUG NAME BILLING CODE BENEFIT TYPE SITE OF SERVICE ALLOWED COVERAGE REQUIREMENTS LIST OF DIAGNOSES CONSIDERED NOT MEDICALLY NECESSARY PHARMACY POLICY STATEMENT Ohio Medicaid Enbrel (etanercept) Must use
New Drugs for Uveitis. Medical Eye Unit St Thomas Hospital
New Drugs for Uveitis Miles Stanford Medical Eye Unit St Thomas Hospital x Epithelium x x Antigen Y Y Y Y IgG m cd4 IL-2 Y m + IL-12 Cytotoxic T B pmn Ig s PG s. LTB4 O - IL-6 TNFα IFNγγ IL-2 Th1 IL-10
Autoantibodies in the Idiopathic Inflammatory Myopathies
Autoantibodies in the Idiopathic Inflammatory Myopathies Steven R. Ytterberg, M.D. Division of Rheumatology Mayo Clinic Rochester, MN The Myositis Association Annual Conference St. Louis, MO Sept. 25,
Index. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Abatacept for eye diseases, 817 for juvenile dermatomyositis, 894 for juvenile idiopathic arthritis, 756, 760 761 Acne, in SAPHO syndrome, 745
Reporting Autoimmune Diseases in Hematopoietic Stem Cell Transplantation
Reporting Autoimmune Diseases in Hematopoietic Stem Cell Transplantation Marcelo C. Pasquini, MD, MSc HVD05_1.ppt Outline Review of autoimmune diseases (AID). Role of transplantation for AID Data collection:
PAEDIATRIC VASCULITIS
PAEDIATRIC VASCULITIS Lawrence Owino Okong o, Mmed (UoN); Mphil. (UCT). Lecturer, Department of Paediatrics and Child Health, University of Nairobi. Paediatrician/ Rheumatologist. OUTLINE Introduction
Immune Modulating Drugs Prior Authorization Request Form
Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:
Is it Autoimmune or NOT! Presented to AONP! October 2015!
Is it Autoimmune or NOT! Presented to AONP! October 2015! Four main jobs of immune system Detects Contains and eliminates Self regulates Protects Innate Immune System! Epithelial cells, phagocytic cells
Juvenile Spondyloarthritis / Enthesitis Related Arthritis (SpA-ERA)
www.printo.it/pediatric-rheumatology/gb/intro Juvenile Spondyloarthritis / Enthesitis Related Arthritis (SpA-ERA) Version of 2016 1. WHAT IS JUVENILE SPONDYLOARTHRITIS/ENTHESITIS- RELATED ARTHRITIS (SpA-ERA)
1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.
LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review
Primary Results Citation 2
Table S1. Adalimumab clinical trials 1 ClinicalTrials.gov Rheumatoid Arthritis 3 NCT00195663 Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study. A multicenter, randomized, double-blind clinical
INFLIXIMAB (REMICADE, INFLECTRA, RENFLEXIS )
UnitedHealthcare Commercial Medical Benefit Drug Policy INFLIXIMAB (REMICADE, INFLECTRA, RENFLEXIS ) Policy Number: 2019D0004X Effective Date: January 1, 2019 Table of Contents Page INSTRUCTIONS FOR USE...
TAKAYASU S ARTERITIS. Second-stage symptoms include:
What is Takayasu s arteritis (TAK)? Takayasu s arteritis (TAK) is a form of vasculitis a family of rare disorders characterized by inflammation of the blood vessels, which can restrict blood flow and damage
ACTEMRA (tocilizumab)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Actemra is an agent in the class of drugs known as biologic disease modifiers. It is used to treat adult onset rheumatoid (RA) arthritis, polyarticular
Emerging Therapies for Lung Fibrosis. Helen Garthwaite Respiratory Registrar/ Clinical Research Fellow
Emerging Therapies for Lung Fibrosis Helen Garthwaite Respiratory Registrar/ Clinical Research Fellow Lung Fibrosis/Interstitial Lung Disease Disease that affects the tissue that supports the lungs alveoli
HORIZON SCANNING: PAEDIATRIC RHEUMATOLOGY UPATE SEPTEMBER 2011
HORIZON SCANNING: PAEDIATRIC RHEUMATOLOGY UPATE SEPTEMBER 2011 The object of these Horizon Scanning reports is to highlight recently completed and ongoing clinical trials, research recommendations and
Infliximab/Infliximab-dyyb DRUG.00002
Infliximab/Infliximab-dyyb DRUG.00002 Override(s) Prior Authorization Step Therapy Medications Remicade (infliximab) Inflectra (inflectra-dyyb) Approval Duration 1 year Comment Intravenous administration
Undifferentiated Connective Tissue Disease and Overlap Syndromes. Mark S. Box, MD
Undifferentiated Connective Tissue Disease and Overlap Syndromes Mark S. Box, MD Overlap Syndromes As many as 25% of patients with rheumatic diseases with systemic symptoms cannot be definitely diagnosed
(minutes for web publishing)
Rheumatology Subcommittee of the Pharmacology and Therapeutics Advisory Committee (PTAC) Meeting held on 17 October 2017 (minutes for web publishing) Rheumatology Subcommittee minutes are published in
Nausheen Khuddus, MD Melissa Elder, MD, PhD
Nausheen Khuddus, MD Melissa Elder, MD, PhD Nausheen Khuddus, MD Pediatric Ophthalmologist and Strabismus Specialist Accent Physicians Gainesville, Florida What Is Uveitis? Uveitis is caused by inflammatory
Decision relating to the funding of TNF inhibitors (Humira and Enbrel) and gabapentin (Neurontin)
9 September 2015 Decision relating to the funding of TNF inhibitors (Humira and Enbrel) and gabapentin (Neurontin) The PHARMAC Board has approved the proposal relating to the funding of the TNF-inhibitor
Dr Daniel Ching. Rheumatology Therapeutic Clinical Trials Centre Timaru
Dr Daniel Ching Rheumatology Therapeutic Clinical Trials Centre Timaru Therapeutic Advances in Rheumatology GP CME Meeting, Dunedin, 18.08.2013 Dr Daniel Ching, MB FRCP FRACP Consultant Rheumatologist,
Curricular Components for Rheumatology EPA
Curricular Components for Rheumatology EPA 1. EPA Title Manage patients with acute or chronic complex multi-system rheumatic disease in an ambulatory, emergency, or inpatient setting. 2. Description of
HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES HUMIRA PEDIATRIC
Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 HUMIRA PEDIATRIC GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the patient currently taking Humira? If
Medication Policy Manual. Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013
Medication Policy Manual Policy No: dru289 Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1,
Orencia (abatacept) DRUG.00040
Market DC Orencia (abatacept) DRUG.00040 Override(s) Prior Authorization Quantity Limit Approval Duration 1 year Medications Comments Quantity Limit Orencia (abatacept) - AGP, VA MCD only 4 vials per 28
Vasculitis in primary connective tissue diseases
Oxford Medicine Online You are looking at 1-10 of 26 items for: MRI rheumatoid MED00240 Vasculitis in primary connective tissue diseases Laura B. Hughes DOI: 10.1093/med/9780199659869.003.0033 Vasculitis
3 rd Appraisal Committee meeting, 28 February 2017 Committee D
Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying antirheumatic drugs Multiple Technology Appraisal 3 rd Appraisal Committee
oimmune_disease
http://en.wikipedia.org/wiki/aut oimmune_disease Autoimmune diseases arise from an overactive immune response of the body against substances and tissues normally present in the body. In other words, the
GRANULOMATOSIS WITH POLYANGIITIS
What is granulomatosis with polyangiitis (GPA)? Granulomatosis with polyangiitis (GPA) is a form of vasculitis a family of rare disorders characterized by inflammation of the blood vessels, which can restrict
TOCILIZUMAB FOR DIFFICULT TO TREAT IDIOPATHIC RETROPERITONEAL FIBROSIS. A PILOT TRIAL
TOCILIZUMAB FOR DIFFICULT TO TREAT IDIOPATHIC RETROPERITONEAL FIBROSIS. A PILOT TRIAL Dr Augusto Vaglio, Dr Federica Maritati Unit of Nephrology, University Hospital of Parma, Via Gramsci 14, 43126 Parma
Clinical Commissioning Policy: Rituximab For ANCA Vasculitis. December Reference : NHSCB/ A3C/1a
Clinical Commissioning Policy: Rituximab For ANCA Vasculitis December 2012 Reference : NHSCB/ A3C/1a NHS Commissioning Board Clinical Commissioning Policy: Rituximab For The Treatment Of Anti-Neutrophil
HORIZON SCANNING: PAEDIATRIC RHEUMATOLOGY UPATE FEBRUARY 2011
HORIZON SCANNING: PAEDIATRIC RHEUMATOLOGY UPATE FEBRUARY 2011 The object of these Horizon Scanning reports is to highlight recently completed and ongoing clinical trials, research recommendations and new
Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi
Differential diagnostics in Rheumatology
Differential diagnostics in Rheumatology number of affected joints lengths of duration Acute monoarthritis Chronic monoarthritis Acute polyarthritis Chronic polyarthritis Acute monoarthritis Infective
ANCA+ VASCULITIDES CYCAZAREM,
ANCA+ VASCULITIDES CYCAZAREM, q Comparison of 3 to 6 mo. oral CYC + CS then azathioprine or oral CYC for 12 mo.+ 10 mg/d CS. After 12 mo all the patients were treated with azathioprine q 150 patients followed
Pharmacy Prior Authorization
Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS Humira (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,